Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MBOAT4 | Q96T53 | 18/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3122488 | 1.00 | GAA (0.45) | GAAHTTSMN1; SMN2MBOAT4ATM | |
| SCHEMBL3871870 | 0.95 | GAA (0.42) | GAAHTTSMN1; SMN2MBOAT4ATM | |
| SCHEMBL303749 | 0.95 | GAA (0.45) | GAAHTTSMN1; SMN2MBOAT4ATM | |
| SCHEMBL3876315 | 0.95 | GAA (0.42) | GAAHTTSMN1; SMN2MBOAT4ATM | |
| SCHEMBL3130141 | 0.95 | GAA (0.45) | GAAHTTSMN1; SMN2MBOAT4ATM | |
| SCHEMBL3133063 | 0.95 | GAA (0.45) | GAAHTTSMN1; SMN2MBOAT4ATM | |
| SCHEMBL3868099 | 0.95 | GAA (0.42) | GAAHTTSMN1; SMN2MBOAT4ATM | |
| SCHEMBL5402153 | 0.95 | GAA (0.45) | GAAHTTSMN1; SMN2MBOAT4ATM | |
| SCHEMBL174682 | 0.92 | GAA (0.45) | GAAHTTSMN1; SMN2MBOAT4ATM | |
| SCHEMBL3121971 | 0.92 | GAA (0.45) | GAAHTTSMN1; SMN2MBOAT4ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171657-A1 | 5,6-Dialkyl-7-Aminoazolopyrimidines, Their Preparation and Their Use for Controlling Harmful Fungi, and Compositions Comprising These Compounds | BASF AKTIENGESELLSCHAFT (DE) | 2008-07-17 | — | — | US | disclosed |
| EP-1856119-A1 | 5,6-DIALKYL-7-AMINO-AZOLOPYRIMIDINES, METHOD FOR THEIR PRODUCTION, THEIR USE FOR CONTROLLING PATHOGENIC FUNGI AND AGENTS CONTAINING SAID COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006092412-A1 | 5,6-DIALKYL-7-AMINO-AZOLOPYRIMIDINES, METHOD FOR THEIR PRODUCTION, THEIR USE FOR CONTROLLING PATHOGENIC FUNGI AND AGENTS CONTAINING SAID COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171657-A1 | 5,6-Dialkyl-7-Aminoazolopyrimidines, Their Preparation and Their Use for Controlling Harmful Fungi, and Compositions Comprising These Compounds | ERG28, AGPS, MTAP | GAA 2802/4885HTT 3858/4885SMN1; SMN2 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.